Ghrelin and GLP-1 functionally antagonize each other through co-localized receptors on vagal afferent neurons — whichever peptide arrives first electrically cancels the effect of the second.
First winswhichever peptide (ghrelin or GLP-1) reaches vagal neurons first blocks the other's feeding signal
What the researchers found
GLP-1 and ghrelin receptors co-localize on vagal afferent neurons innervating the stomach. Each peptide abolishes the electrical and feeding effects of the subsequently administered peptide. Ghrelin generates hyperpolarizing current while GLP-1 generates depolarizing current in isolated nodose ganglia neurons.
Why it matters
Understanding how hunger and satiety signals interact at the neural level is fundamental to developing better obesity and appetite disorder treatments. This mutual antagonism through shared neurons reveals a key regulatory checkpoint.
The numbers in context
30-min pre-administration of either peptide abolished the other's feeding effect; vagal afferent pathway confirmed.
How the study worked
In vivo feeding studies in rats and mice with sequential peptide administration. Fos expression in nodose ganglia. Electrophysiology of vagal afferents. Calcium imaging in isolated nodose ganglia neurons. Patch-clamp experiments measuring ghrelin and GLP-1 currents.
Who was studied
Rats and mice in acute feeding studies
What this study cannot tell us
Animal study — human vagal neuron signaling may differ. The timing dependency (first peptide 'wins') observed in acute experiments may not fully apply to chronic drug administration. In vivo confirmation of electrophysiological findings is indirect.
How to read the evidence
Rigorous multi-method animal study combining behavioral, electrophysiological, imaging, and patch-clamp evidence. Mechanistic clarity is strong but human translation needs confirmation.
When this study was published
Published in 2020. This vagal interaction mechanism is relevant to understanding how GLP-1 drugs like semaglutide suppress appetite.
The bigger picture
GLP-1 drugs like semaglutide are revolutionizing obesity treatment but we're still learning exactly how they work. This study reveals that one key mechanism is direct competition with ghrelin signaling at the vagal nerve level — the body's main gut-brain communication line.
Questions still open
- Does chronic GLP-1 agonist therapy maintain its ability to suppress ghrelin signaling over time?
- Could dual ghrelin antagonist/GLP-1 agonist combinations enhance weight loss beyond GLP-1 alone?
- How does this vagal competition mechanism contribute to the appetite-suppressing effects of bariatric surgery?
Common questions
How do ghrelin and GLP-1 compete in the body?
Why is this relevant to weight loss drugs?
Read the original research
Functional interaction between Ghrelin and GLP-1 regulates feeding through the vagal afferent system.
Scientific reports, 10(1), 18415
Citation
Zhang, Weidong; Waise, T M Zaved; Toshinai, Koji; Tsuchimochi, Wakaba; Naznin, Farhana; Islam, Md Nurul; Tanida, Ryota; Sakoda, Hideyuki; Nakazato, Masamitsu. (2020). Functional interaction between Ghrelin and GLP-1 regulates feeding through the vagal afferent system.. Scientific reports, 10(1), 18415. https://doi.org/10.1038/s41598-020-75621-5